How has been the historical performance of Aurobindo Pharma?

Revenue and Profit Growth

Over the seven-year period ending March 2025, Aurobindo Pharma’s net sales have shown a consistent upward trend, rising from ₹19,563.55 crores in 2019 to ₹31,723.73 crores in 2025. This represents a compound growth trajectory, with notable acceleration in recent years. The total operating income mirrors this growth, reflecting the company’s expanding market presence and operational scale.

Operating profit before depreciation and interest (PBDIT) excluding other income increased from ₹3,891.66 crores in 2019 to ₹6,582.79 crores in 2025, indicating improved operational efficiency despite rising raw material and employee costs. The operating profit margin has remained relatively stable, hovering around 21% in recent years, underscoring consistent profitability management.

Profit after tax (PAT) has also followed a positive trajectory, rising from ₹2,361.80 crores in 2019 to ₹3,515.26 crores in 2025. The PAT margin, while fluctuating, has maintained a healthy level above 11% in the latest fiscal years, reflecting the company’s ability to convert revenue growth into net earnings effectively.

Cost Structure and Margins

The company’s raw material costs have increased in absolute terms from ₹7,444.99 crores in 2019 to ₹10,736.76 crores in 2025, reflecting higher production volumes and input prices. Purchase of finished goods and employee costs have also risen steadily, with employee expenses growing from ₹2,584.87 crores to ₹4,475.62 crores over the same period, indicating investment in human capital to support growth.

Despite these rising costs, Aurobindo Pharma has managed to maintain a gross profit margin above 20% in recent years, a testament to its pricing power and operational control. The company’s interest expenses have increased but remain manageable relative to earnings, with interest costs rising to ₹457.24 crores in 2025 from ₹162.66 crores in 2019, partly due to increased borrowings to fund expansion.

Balance Sheet Strength and Capitalisation

Shareholders’ funds have grown significantly, from ₹16,824.67 crores in 2020 to ₹32,653.32 crores in 2025, supported by accumulated reserves and retained earnings. The book value per share has nearly doubled from ₹287.16 in 2020 to ₹562.21 in 2025, reflecting enhanced net asset value per equity share.

Total liabilities have increased in line with business expansion, reaching ₹48,492.01 crores in 2025 from ₹28,764.54 crores in 2020. Notably, total debt rose to ₹7,941.68 crores in 2025 from ₹5,561.97 crores in 2020, indicating increased leverage but still within a range that supports growth initiatives.

Capital expenditure is evident in the rising gross block and capital work in progress, with net block assets increasing from ₹9,396.47 crores in 2020 to ₹14,499.78 crores in 2025, signalling ongoing investments in manufacturing and infrastructure.

Cash Flow and Liquidity

Cash flow from operating activities has fluctuated but shows an overall positive trend, with ₹3,924 crores generated in 2025 compared to ₹4,381 crores in 2020. The company has maintained a healthy cash and bank balance, rising to ₹8,235.49 crores in 2025 from ₹2,842.15 crores in 2020, enhancing liquidity and financial flexibility.

Investing activities have seen significant outflows, reflecting capital expenditure and strategic investments, while financing activities have varied, including debt repayments and borrowings. Net cash inflow in 2025 stood at ₹2,178 crores, a marked improvement from prior years, indicating stronger cash generation and prudent financial management.

Summary and Investor Implications

Aurobindo Pharma’s historical performance reflects a company on a steady growth path, balancing revenue expansion with disciplined cost management and strategic capital investments. The consistent rise in net sales and profits, alongside a strengthening balance sheet and improved cash position, suggests a resilient business model well-positioned in the pharmaceutical sector.

While the company has increased its debt levels to fund growth, the leverage remains controlled relative to earnings and asset base. Margins have been stable, and earnings per share have shown significant improvement, enhancing shareholder value over time.

Investors analysing Aurobindo Pharma should consider its demonstrated ability to grow revenues and profits while investing in capacity and maintaining liquidity. The company’s financial metrics indicate a mature midcap with potential for sustained performance, though monitoring debt levels and margin trends will be crucial for future assessments.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →